Drug Approval | November 22, 2021
European Commission approves Roche’s Gavreto
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The centre has an initial capacity of 500 FTEs
The company will provide the technical and financial resources to support the study
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The company is a medical dictation solution used by medical practitioners
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
